Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Issued (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Shares Issued for 10 consecutive years, with $323000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 99.73% to $323000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $323000.0 through Dec 2025, down 99.74% year-over-year, with the annual reading at $323000.0 for FY2025, 99.74% down from the prior year.
  • Shares Issued for Q4 2025 was $323000.0 at Cartesian Therapeutics, down from $121.6 million in the prior quarter.
  • The five-year high for Shares Issued was $9.4 billion in Q2 2022, with the low at -$172000.0 in Q2 2021.
  • Average Shares Issued over 4 years is $1.6 billion, with a median of $199000.0 recorded in 2021.
  • The sharpest move saw Shares Issued crashed 117.27% in 2021, then skyrocketed 10585356.18% in 2022.
  • Over 4 years, Shares Issued stood at -$161000.0 in 2021, then skyrocketed by 5851687.58% to $9.4 billion in 2022, then plummeted by 98.71% to $121.6 million in 2024, then tumbled by 99.73% to $323000.0 in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $323000.0, $121.6 million, and $2.6 million for Q4 2025, Q4 2024, and Q3 2024 respectively.